Kiladjian, JJ; Al-Ali, HK; Mayer, J; Tomuleasa, C; Palandri, F; Beggiato, E; Gutierrez, VG; Reiter, A; Heidel, F; Tybor, JG; Lazaroiu, M; Alvarez-Larran, A; Dohner, K; Breccia, M; Illes, A; Grosicki, S; James, C; Marin, FF; Terpos, E; Crisan, A; Buxhofer-Ausch, V; Schmidt, S; Woelfler, A; Nagy, Z; Koschmieder, S; Cerna, O; Pappa, V; Sacha, T; Schlager, S; Empson, V; Unger, M; Krejcy, K; Klade, C.
Ropeginterferon alfa-2b in essential thrombocythemia of all risk levels ineligible for standard cytoreduction: 12-month primary endpoint analysis from the ROP-ET phase 3 study
BLOOD. 2025; 146: 485-486.
Doi: 10.1182/blood-2025-485
Web of Science
FullText
FullText_MUG